Proximity ligation assay evaluates IDH1R132H presentation in gliomas

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 593-606

  Bunse, Lukas ^a,b   Schumacher, Theresa ^a,b   Sahm, Felix ^a,b   Pusch, Stefan ^a,b   Oezen, Iris ^a,b   Rauschenbach, Katharina ^a,b   Gonzalez, Marina ^a,b   Solecki, Gergely ^a,b   Osswald, Matthias ^a,b   Capper, David ^a,b   Wiestler, Benedikt ^a,b   Winkler, Frank ^a,b   Herold Mende, Christel ^b   Von Deimling, Andreas ^a,b   Wick, Wolfgang ^a,b   Platten, Michael ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; ISOCITRATE DEHYDROGENASE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; NY ESO 1 ANTIGEN; PARAFFIN; CANCER VACCINE; HLA ANTIGEN CLASS 2; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ARTICLE; ASSAY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; GENE MUTATION; GLIOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROXIMITY LIGATION ASSAY; TISSUE SECTION; ADULT; AGED; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BRAIN TUMOR; CLINICAL TRIAL; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; EPITOPES; FEMALE; GLIOMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION, MISSENSE;

EID: 84961293591     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77780     Document Type: Article

References (43)

1. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
2. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol. 2004;5(11):681-689.
3. Mocellin S, Semenzato G, Mandruzzato S, Riccardo Rossi C. Part II: Vaccines for haematological malignant disorders. Lancet Oncol. 2004;5(12):727-737.
4. Prins RM, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615.
5. Sampson JH, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773-2779.
6. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192-1198.
7. Zhao LL, Xu KL, Wang SW, Hu BL, Chen LR. Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas. Histopathology. 2012;61(4):726-736.
8. Jager E, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A. 2000;97(9):4760-4765.
9. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36(Web Server issue):W509-W512.
10. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 2009;10:296.
11. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-219.
12. Regner M, Claesson MH, Bregenholt S, Ropke M. An improved method for the detection of peptideinduced upregulation of HLA-A2 molecules on TAP-deficient T2 cells. Exp Clin Immunogenet. 1996;13(1):30-35.
13. Dutoit V, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain. 2012;135(pt 4):1042-1054.
14. Schumacher T, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324-327.
15. Weiler M, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014;111(1):409-414.
16. Schweizer L, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125(5):651-658.
17. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597-602.
18. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
19. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
20. Capper D, et al. Characterization of R132H mutationspecific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20(1):245-254.
21. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118(5):599-601.
22. Andersson G. Evolution of the human HLA-DR region. Front Biosci. 1998;3:d739-d745.
23. Ayyoub M, et al. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1∗0101 tetramers. Clin Cancer Res. 2010;16(18):4607-4615.
24. Zarour HM, et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002;62(1):213-218.
25. Choi BD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009;19(4):713-723.
26. Sampson JH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.
27. Sensi M, Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res. 2006;12(17):5023-5032.
28. Accolla RS, Tosi G. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. J Transl Med. 2012;10:154.
29. Hunder NN, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698-2703.
30. Quezada SA, et al. Tumor-reactive CD4 (+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637-650.
31. Chou WC, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086-4094.
32. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058-1066.
33. Ward PS, et al. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-234.
34. Amary MF, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334-343.
35. Arai M, Nobusawa S, Ikota H, Takemura S, Nakazato Y. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol. 2012;29(4):201-206.
36. Wang P, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32(25):3091-3100.
37. Sahm F, et al. Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2012;69(4):523-526.
38. Lehtinen M, Stellato G, Hyoty H, Nieminen P, Vesterinen E, Paavonen J. A T-helper cell epitope overlaps a major B-cell epitope in human papillomavirus type 18 E2 protein. APMIS. 1992;100(11):1022-1026.
39. Rees RC, Mian S. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother. 1999;48(7):374-381.
40. Takamura Y, et al. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia. 2004;45(4):392-405.
41. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 2007;8:238.
42. Campos B, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010;16(10):2715-2728.
43. Balss J, et al. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol. 2012;124(6):883-891.